This panel discussion will focus on fluid biomarkers and their association with long-term visual outcomes for patients with neovascular age-related macular degeneration. The faculty will debate key clinical trial data/post hoc analyses in addition to real-world experience.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.







